Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Moogene Medi Co., Ltd. Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.	South Korea	322970
MORISHITA JINTAN CO.,LTD. Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.	Japan	4524
MUROMACHI CHEMICALS INC. A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.	Japan	4885
MUSTANG BIO, INC. Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.	United States of America	MBIO
MYUNGMOON PHARM CO.,LTD Develops, manufactures, and commercializes prescription & OTC medicines for global markets.	South Korea	017180
Nanexa AB Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.	Sweden	NANEXA
Nanobiotix Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.	France	NANO
Nanobiotix S.A. Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.	United States of America	NBTX
Nanoform Finland OYJ Pharma tech firm engineering nanoparticles to enhance drug performance and development.	Finland	NANOFH
NanoGroup S.A. Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.	Poland	NNG